Volitionrx ltd VNRX.US 總覽分析
VNRX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
VNRX 近期報酬表現
-2.56%
Volitionrx ltd
3.56%
同產業平均
1.47%
S&P500
與 VNRX 同產業的標的表現
- KZR Kezar life sciences inc價值 1 分趨勢 2 分波段 4 分籌碼 2 分股利 1 分查看更多
VNRX 公司資訊
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.